Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company developing fusion protein drugs for the treatment of cancer patients based on its Targeted Protein Therapeutics (TPTs) platform. In February 2021, the FDA accepted the company’s Vicineum™ BLA submission, which represents a potential best-in-class treatment for non-muscle invasive bladder cancer.